STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 213.4

Change

+3.05 (+1.45)%

Market Cap

USD 0.68B

Volume

545.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.19 (+0.42%)

USD 60.76B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-0.20 (-0.03%)

USD 13.44B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.03 (+0.01%)

USD 12.33B
WRD:PA HSBC MSCI World UCITS ETF

+0.02 (+0.04%)

USD 10.94B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-2.30 (-0.45%)

USD 8.88B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+1.20 (+0.49%)

USD 8.60B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.30 (+0.08%)

USD 7.71B
HHH:PA HSBC S&P 500 UCITS ETF

-0.02 (-0.03%)

USD 7.47B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.02 (+0.10%)

USD 6.81B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.36 (-0.22%)

USD 5.39B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.86% 51% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.86% 51% F 53% F
Trailing 12 Months  
Capital Gain 4.35% 22% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.35% 19% F 46% F
Trailing 5 Years  
Capital Gain 29.84% 50% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.84% 47% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.24% 56% F 61% D-
Dividend Return 9.24% 55% F 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.17% 75% C 93% A
Risk Adjusted Return 113.18% 92% A 97% N/A
Market Capitalization 0.68B 73% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike